Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
(2015). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 May 2015
|
| In: |
Leukemia and lymphoma
Year: 2015, Jahrgang: 56, Heft: 12, Pages: 3320-3328 |
| ISSN: | 1029-2403 |
| Online-Zugang: | Verlag, Volltext: https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1030641
|
| Verfasserangaben: | Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A. Chanan-Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin Huang, Yuqiu Jiang, Sindy T. Kim, Sophia Randolph & Selina Chen-Kiang |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1727461835 | ||
| 003 | DE-627 | ||
| 005 | 20220818181035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200819s2015 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1727461835 | ||
| 035 | |a (DE-599)KXP1727461835 | ||
| 035 | |a (OCoLC)1341355931 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Niesvizky, Ruben |e VerfasserIn |0 (DE-588)1023118777 |0 (DE-627)717709515 |0 (DE-576)366420615 |4 aut | |
| 245 | 1 | 0 | |a Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma |c Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A. Chanan-Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin Huang, Yuqiu Jiang, Sindy T. Kim, Sophia Randolph & Selina Chen-Kiang |
| 246 | 3 | 3 | |a Phase 1 / 2 study of cyclin-dependent kinase (CDK) 4 / 6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed / refractory multiple myeloma |
| 264 | 1 | |c 15 May 2015 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.08.2020 | ||
| 520 | |a (2015). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. | ||
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 56(2015), 12, Seite 3320-3328 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:56 |g year:2015 |g number:12 |g pages:3320-3328 |g extent:9 |a Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1030641 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200819 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 999 | |a KXP-PPN1727461835 |e 3741207772 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"titleAlt":[{"title":"Phase 1 / 2 study of cyclin-dependent kinase (CDK) 4 / 6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed / refractory multiple myeloma"}],"language":["eng"],"person":[{"role":"aut","given":"Ruben","display":"Niesvizky, Ruben","family":"Niesvizky"},{"display":"Raab, Marc-Steffen","family":"Raab","given":"Marc-Steffen","role":"aut"}],"id":{"eki":["1727461835"]},"recId":"1727461835","relHost":[{"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}],"pubHistory":["1.1989/90 -"],"note":["Gesehen am 08.09.15"],"origin":[{"dateIssuedDisp":"1989-","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare","publisherPlace":"London [u.a.] ; London [u.a.]"}],"disp":"Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaLeukemia and lymphoma","type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"324746237","id":{"issn":["1029-2403"],"zdb":["2030637-4"],"eki":["324746237"]},"language":["eng"],"part":{"pages":"3320-3328","year":"2015","text":"56(2015), 12, Seite 3320-3328","issue":"12","volume":"56","extent":"9"}}],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A. Chanan-Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin Huang, Yuqiu Jiang, Sindy T. Kim, Sophia Randolph & Selina Chen-Kiang"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma","title":"Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma"}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"15 May 2015"}],"note":["Gesehen am 19.08.2020"]} | ||
| SRT | |a NIESVIZKYRPHASE12STU1520 | ||